Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01260
|
|||||
| Drug Name |
Tadalafil
|
|||||
| Synonyms |
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; ADCIRCA; Acdirca; Cialis; Cialis (TN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; GF 196960; GF-196960; IC 351; IC-351; ICOS 351; Ic351; KS-1117; Lilly brand of tadalafil; Tadalafil (JAN/USAN/INN); Tadalafil [USAN]; Tadanafil
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Benign prostatic hyperplasia [ICD11:GA90] | Approved | [1] | |||
| Erectile dysfunction [ICD11:HA01] | Approved | [1] | ||||
| Pulmonary arterial hypertension [ICD11:BB01.0] | Approved | [1] | ||||
| Therapeutic Class |
Antiimpotence Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H19N3O4
|
|||||
| Canonical SMILES |
CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36
|
|||||
| InChI |
InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1
|
|||||
| InChIKey |
WOXKDUGGOYFFRN-IIBYNOLFSA-N
|
|||||
| CAS Number |
CAS 171596-29-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 389.4 | Topological Polar Surface Area | 74.9 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
585746
,833257
,7849070
,7980303
,10235225
,12015128
,14756405
,14805118
,26719828
,44439099
,46386604
,46393582
,46507646
,46515102
,48631155
,49665805
,49666420
,49681754
,50070180
,50070554
,50071306
,50930588
,53789230
,57338564
,71826083
,92308507
,103205141
,104253184
,104386552
,118046114
,124658965
,124757304
,124801305
,124976968
,125164108
,126670668
,126730649
,129612837
,131407413
,134337906
,134358339
,135067956
,137002812
,142183965
,144075910
,144206195
,152031978
,152344458
,160709391
,160821591
|
|||||
| ChEBI ID |
CHEBI:71940
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Tadalafil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. Biol Pharm Bull. 2017;40(8):1314-1319. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.